非布司他联合双氯芬酸钠缓释片治疗痛风性关节炎伴高尿酸血症的疗效和安全性

The efficacy and safety of febuxostat combined with diclofenac sodium sustained release tablets in the treatment of gouty arthritis with hyperuricemia

目的探讨非布司他联合双氯芬酸钠缓释片治疗痛风性关节炎伴高尿酸血症患者的疗效和安全性。方法选取2020年10月至2021年10月抚州市妇幼保健院收治的62例痛风性关节炎伴有高尿酸血症患者作为研究对象,随机分为对照组与观察组,每组31例。对照组给予双氯芬酸钠缓释片治疗,观察组给予非布司他联合双氯芬酸钠缓释片治疗。比较两组治疗前后临床症状、炎症因子[肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、白细胞介素-1β(IL-1β)]水平、临床疗效和不良反应发生情况。结果治疗后,观察组关节肿胀、关节疼痛和关节活动受限评分均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);治疗后,两组TNF-α、IL-6、IL-1β水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);观察组治疗总有效率为96.77%,高于对照组的70.97%,差异有统计学意义(P<0.05);两组不良反应发生率比较差异无统计学意义。结论非布司他联合双氯芬酸钠缓释片治疗痛风性关节炎伴高尿酸血症患者疗效显著,可改善患者炎症因子水平,促进免疫功能恢复平衡状态,缓解临床症状,安全性较高,值得临床推广应用。

Objective To explore the efficacy and safety of febuxostat combined with diclofenac sodium sustained release tablets in the treat-ment of gouty arthritis with hyperuricemia.Methods 62 patients with gouty arthritis accompanied by hyperuricemia admitted to Fuzhou Maternal and Child Health Hospital from October 2020 to October 2021 were selected as the study subjects,and they were randomly divided into the con-trol group and the observation group,with 31 cases in each group.The control group was treated with sustained-release diclofenac sodium tablets,while the observation group was treated with febuxostat combined with diclofenac sodium sustained release tablets,the clinical symptoms and in-flammatory factors(tumor necrosis factor-α[TNF-α],interleukin-6[IL-6],interleukin-1β[IL-1β])level before and after treatment,clinical effi-cacy and incidence of adverse reactions were compared between the two groups.Results After treatment,the scores of joint swelling,joint pain and joint mobility limitation in the observation group were lower than before treatment,and observation group was lower than control group,the differences were statistically significant(P<0.05).After treatment,the levels of TNF-α,IL-6 and IL-1βof the two groups were lower than before treatment,and observation group was lower than control group,the differences were statistically significant(P<0.05).The total effective rate in the observation group was 96.77%,which was higher than 70.97%in the control group,and the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups.Conclusion Febuxostat combined with diclofe-nac sodium sustained release tablets has obvious curative effect on patients with gouty arthritis with hyperuricemia,which can improve the level of inflammatory factors,promote the recovery of immune function and relieve clinical symptoms,it is safe and worthy of clinical promotion and ap-plication.